gri is a development stage biotech company fundamentally changing the way inflammatory disease is treated. gri’s natural killer t (nkt) cell-based therapies are being developed for liver disease and acute liver failure. nkt cells share properties of both nk and t cells and are a functional link between the innate and adaptive immune responses. type 1 nkt cells play a critical role in initiating and propagating the inflammatory response and the hepatic injury that is observed in liver disease. gri’s lead program, gri-0621, is an inhibitor of type i nkt cells and is being developed as a novel oral therapeutic for acute liver failure.
Company profile
Ticker
GRI
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Vallon Pharmaceuticals, Inc.
SEC CIK
Corporate docs
IRS number
824369909
GRI stock data
Latest filings (excl ownership)
8-K
GRI Bio Reports Full Year 2023 Financial Results and Provides Corporate Update
1 Apr 24
424B3
Prospectus supplement
28 Mar 24
424B3
Prospectus supplement
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
424B3
Prospectus supplement
2 Feb 24
8-K
GRI Bio Announces Pricing of $5.5 Million Public Offering
2 Feb 24
424B4
Prospectus supplement with pricing info
2 Feb 24
EFFECT
Notice of effectiveness
2 Feb 24
S-1/A
IPO registration (amended)
31 Jan 24
S-1/A
IPO registration (amended)
30 Jan 24
Latest ownership filings
SC 13G/A
Altium Capital Management LP
13 Feb 24
4
Leanne Kelly
26 Sep 23
4
David Leslie Szekeres
14 Aug 23
4
CAMILLA V SIMPSON
14 Aug 23
4
Roelof Rongen
14 Aug 23
4
David Charles Baker
14 Aug 23
SC 13G
Altium Capital Management LP
3 May 23
SC 13G
TEP Biotech, LLC
2 May 23
SC 13D
Chaturvedi Vipin
25 Apr 23
SC 13D
Agro Albert
25 Apr 23
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | |
---|---|---|---|---|
Revenue | ||||
Cost of revenue | ||||
Operating income | ||||
Operating margin | ||||
Net income | ||||
Net profit margin | ||||
Cash on hand | ||||
Change in cash | ||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 3.49 mm | 3.49 mm | 3.49 mm | 3.49 mm | 3.49 mm | 3.49 mm |
Cash burn (monthly) | 437.00 k | (no burn) | 813.00 k | 1.42 mm | 437.00 k | 860.33 k |
Cash used (since last report) | 2.99 mm | n/a | 5.56 mm | 9.73 mm | 2.99 mm | 5.88 mm |
Cash remaining | 500.36 k | n/a | -2.07 mm | -6.24 mm | 500.36 k | -2.39 mm |
Runway (months of cash) | 1.1 | n/a | -2.5 | -4.4 | 1.1 | -2.8 |
Institutional ownership, Q2 2023
43.9% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 5 |
Opened positions | 5 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 5.16 bn |
Total shares | 1.40 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Altium Capital Management | 1.18 mm | $5.01 bn |
TEP Biotech | 204.91 k | $73.77 mm |
Geode Capital Management | 14.88 k | $63.83 mm |
Tower Research Capital | 2.58 k | $10.95 mm |
UBS UBS Group AG - Registered Shares | 899.00 | $3.82 mm |
Proequities | 0.00 | $0.00 |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
22 Sep 23 | Leanne M. Kelly | Stock Option Common Stock | Grant | Acquire A | No | No | 1.52 | 83,333 | 126.67 k | 83,333 |
10 Aug 23 | Camilla V Simpson | Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 34,483 | 100.00 k | 34,483 |
10 Aug 23 | Roelof Rongen | Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 34,483 | 100.00 k | 34,483 |
10 Aug 23 | David Leslie Szekeres | Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 34,483 | 100.00 k | 34,483 |
10 Aug 23 | David Charles Baker | Stock Option Common Stock | Grant | Acquire A | No | No | 2.9 | 34,483 | 100.00 k | 34,483 |
News
GRI Bio Expands Intellectual Property Protection For Proprietary Natural Killer T Cell Modulators With Issuance Of Korea Patent
16 Apr 24
12 Health Care Stocks Moving In Monday's After-Market Session
8 Apr 24
12 Health Care Stocks Moving In Thursday's After-Market Session
4 Apr 24
12 Health Care Stocks Moving In Tuesday's Intraday Session
2 Apr 24
GRI Bio Announces Notice Of Allowance For Canadian Patent Covering Proprietary Natural Killer T Cell Modulators
14 Mar 24
Press releases
GRI Bio Expands Intellectual Property Protection for Proprietary Natural Killer T (NKT) Cell Modulators with Issuance of Korea Patent
16 Apr 24
GRI Bio Announces Abstract Accepted for Poster Presentation at the 2024 American Thoracic Society International Conference
8 Apr 24
GRI Bio Announces Notice of Allowance for Canadian Patent Covering Proprietary Natural Killer T (NKT) Cell Modulators
14 Mar 24
GRI Bio Announces Reverse Stock Split
26 Jan 24